VILTADI, MICHELA
VILTADI, MICHELA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
2022 Mologni, L; Tardy, S; Zambon, A; Orsato, A; Bisson, W; Ceccon, M; Viltadi, M; D'Attoma, J; Pannilunghi, S; Vece, V; Bertho, J; Goekjian, P; Scapozza, L; Gambacorti-Passerini, C
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase
2022 Mologni, L; Orsato, A; Zambon, A; Tardy, S; Bisson, W; Schneider, C; Ceccon, M; Viltadi, M; D'Attoma, J; Pannilunghi, S; Vece, V; Gueyrard, D; Bertho, J; Scapozza, L; Goekjian, P; Gambacorti-Passerini, C
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
2019 Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; Redaelli, S; Massimino, L; Wang, P; Khandelwal, P; Citterio, S; Viltadi, M; Bombelli, S; Rigolio, R; Perego, R; Boultwood, J; Morotti, A; Saglio, G; Dong-Wook, K; Branford, S; Gambacorti Passerini, C; Piazza, R
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL)
2019 Cassin, R; Mattiello, V; Viltadi, M; D'Aliberti, D; Piazza, R; Gambacorti-Passerini, C; Gianelli, U; Neri, A; Cortelezzi, A; Reda, G
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
2018 Mologni, L; Costanza, M; Sharma, G; Viltadi, M; Massimino, L; Citterio, S; Purgante, S; Raman, H; Pirola, A; Zucchetti, M; Piazza, R; Gambacorti-Passerini, C
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
2012 Redaelli, S; Mologni, L; Rostagno, R; Piazza, R; Magistroni, V; Ceccon, M; Viltadi, M; Flynn, D; GAMBACORTI PASSERINI, C
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors
2011 af Gennäs, G; Mologni, L; Ahmed, S; Rajaratnam, M; Marin, O; Lindholm, N; Viltadi, M; GAMBACORTI PASSERINI, C; Scapozza, L; Yli Kauhaluoma, J
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells
2011 Magistroni, V; Mologni, L; Sanselicio, S; Reid, J; Redaelli, S; Piazza, R; Viltadi, M; Bovo, G; Strada, G; Grasso, M; Gariboldi, M; GAMBACORTI PASSERINI, C
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036
2010 Redaelli, S; Mologni, L; Rostagno, R; Piazza, R; Viltadi, M; Wise, S; Flynn, D; GAMBACORTI PASSERINI, C
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib
2010 Redaelli, S; Boschelli, F; Perini, P; Pirola, A; Viltadi, M; GAMBACORTI PASSERINI, C
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein
2009 Perini, P; Redaelli, S; Piazza, R; Viltadi, M; Boschelli, F; GAMBACORTI PASSERINI, C